由甲氧苄啶-磺胺甲恶唑引起的儿童线状IgA大疱性疾病。
Childhood linear IgA bullous disease induced by trimethoprim-sulfamethoxazole.
作者信息
Nantel-Battista Mélissa, Al Dhaybi Rola, Hatami Afshin, Marcoux Danielle, Desroches Anne, Kokta Victor
机构信息
Division of Dermatology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
出版信息
J Dermatol Case Rep. 2010 Dec 19;4(3):33-5. doi: 10.3315/jdcr.2010.1053.
BACKGROUND
Linear IgA bullous disease (LABD) is a rare mucocutaneous autoimmune subepidermal blistering disease that can affect children mostly of pre-school age. As many as two-thirds of LABD are related to drug ingestion, particularly certain antibiotics, non-steroidal anti-inflammatory drugs and diuretics.
MAIN OBSERVATION
We describe a 3-year-old boy who presented a CMV infection followed by LABD induced by trimtheporim-sulfametoxazole. To our knowledge, this is the first reported case of trimethoprim-sulfamethoxazole that was confirmed by a rechallenge.
CONCLUSIONS
Most cases of drug-induced LABD are patients being treated with multiple systemic drugs that could induce the LABD. In the lack of suitable alternative treatment, the identification of the causative drug can be achieved by a rechallenge under close medical surveillance.
背景
线状IgA大疱性疾病（LABD）是一种罕见的黏膜皮肤自身免疫性表皮下大疱性疾病，主要影响学龄前儿童。多达三分之二的LABD与药物摄入有关，尤其是某些抗生素、非甾体抗炎药和利尿剂。
主要观察结果
我们描述了一名3岁男孩，他在巨细胞病毒感染后出现了由甲氧苄啶 - 磺胺甲恶唑诱发的LABD。据我们所知，这是首例经再激发试验证实的甲氧苄啶 - 磺胺甲恶唑诱发LABD的病例。
结论
大多数药物性LABD病例是正在接受多种可能诱发LABD的全身性药物治疗的患者。在缺乏合适替代治疗方法的情况下，通过在密切医疗监测下进行再激发试验可以确定致病药物。
Zotero 插件